PBAC's latest decision on Selinexor: Recommended with restriction (2022). Considered for Relapsed and/or refractory multiple myeloma (RRMM) in adult patients who have received at least one prior therapy, in combination with bortezomib and dexamethasone.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2021
Submissions
5
2021 → 2022
Eligible population
Adult patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy, treated with selinexor in combination with bortezomib and dexamethasone.
Therapy area
Oncology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
PFS
Pivotal trial size
403 patients
Key trials
BOSTON, ENDEAVOR
Comparator
carfilzomib + dexamethasone
Economic model
Cost-minimisation
ICER note
Cost-minimisation approach (CMA) used; no ICER calculated by design.
Submission history
Jul 2021: Not recommended · Authority Required
Jul 2021: Recommended with restriction · Authority Required
Jul 2021: Not recommended · Authority Required
Mar 2022: Recommended with restriction · Authority Required
Nov 2022: Recommended with restriction · Authority Required